1 BTC
=
- USD
Sensei Biotherapeutics, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Sensei Biotherapeutics, Inc. Common Stock
Sensei Biotherapeutics Inc is a clinical-stage biotechnology company engaged in the development of therapies targeting cancer through multi-node inhibition of oncogenic pathways. The company's lead program, PIKTOR, is an investigational oral combination therapy designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway and is being evaluated for the treatment of endometrial and breast cancers. In addition, the company is advancing other pipeline programs targeting tumor metabolism and signaling pathways.
Market Statistics
Trading Metrics
How to Buy SNSE
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy SNSE
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesA new generation of immuno-oncology therapies targeting historically immunotherapy-resistant solid tumors like prostate and pancreatic cancer is advancing rapidly through clinical trials in 2026. Four distinct mechanistic approaches—including NK cell engagers, oncolytic virus immune-primers, and tumor microenvironment-conditional antibodies—are being developed by multiple biotech companies, with over $1.7 billion in dealmaking activity. GT Biopharma's GTB-5550 NK cell engager and Vir Biotechnology's VIR-5500 PSMA-targeted T-cell engager represent leading programs in this emerging therapeutic landscape.
Institutional investors are rotating capital toward clinical-stage biotech companies focused on precision medicine, with the oncology precision medicine market projected to reach $303 billion by 2035. Five companies—Oncolytics Biotech, OS Therapies, Sensei Biotherapeutics, Atossa Therapeutics, and Tango Therapeutics—are advancing promising cancer treatments with strong clinical data and FDA support, positioning themselves for potential M&A activity as major pharma companies seek differentiated assets.
Sensei Biotherapeutics surged 230% on Wednesday following its acquisition of Faeth Therapeutics and a concurrent $200 million private investment. The deal brings PIKTOR, an investigational oral combination targeting the PI3K/AKT/mTOR pathway, into Sensei's pipeline. The company plans to advance PIKTOR through Phase 2 trials in advanced endometrial cancer and Phase 1b trials in HR+/HER2- advanced breast cancer by year-end 2026. Shares reached a new 52-week high at $30.12.
Sensei Biotherapeutics announced promising Phase 1/2 trial results for solnerstotug, a monoclonal antibody targeting VISTA, showing 50% 6-month progression-free survival in PD-(L)1 resistant tumors at the 15 mg/kg dose, with plans to advance to Phase 2 studies in Non-Small Cell Lung Cancer and Merkel Cell Carcinoma.
VISTA inhibitors are an emerging class of immunotherapeutic agents with significant potential in treating cancer and autoimmune diseases. Several companies are actively pursuing VISTA inhibitors, which offer a novel mechanism of action and broad applicability, but also face challenges such as complex development landscape and competition from existing therapies.
